University of Tokyo's RCAST, Fujitsu, and Kowa Successfully Create Promising New Compounds to Fight Drug-Resistant Cancer
Use IT-based drug discovery to develop effective compounds
TOKYO, Jun, 13 2018 - (JCN Newswire) - The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs. In order to link the results of this research to the creation of new drugs, Kowa intends to improve upon the small molecule compounds discovered through this research.
Details of the Research and the Division of Responsibilities
Fujitsu and RCAST began joint research on IT-based drug discovery in June 2011, with Kowa joining in July, conducting research projects around multiple drug discovery targets. This particular joint research project began in December 2015, selecting a drug-resistant oncogenic protein as a drug discovery target. Fujitsu used IT-based drug discovery to design a small molecule compound that featured inhibitory activity(1), and then Kowa synthesized the compound and assessed its inhibitory activity in experiments. RCAST took on the role of providing information on drug discovery targets based from a medical perspective. Fujitsu and Fujitsu Laboratories Ltd. additionally made repeated improvements to the IT-based drug discovery technologies during the course of the joint research project, increasing both accuracy and performance.
Results of the Joint Research
In this joint research, Fujitsu leveraged its proprietary technologies to provide Kowa with chemical structures with the anticipated effect of decreasing the activities of the target protein. Specifically, Fujitsu incorporated drug candidate compound design technology(2) and the drug discovery insights it has previously accumulated, and designed synthetic accessible small molecule compounds using computers. Next, the binding affinity of each compound with the target protein is calculated to narrow down the selection using the M2BAR method(3), which is an improvement on high precision activity prediction technology(4). Fujitsu also took into consideration the results of high precision conformational analysis(5) based on quantum mechanics. Kowa synthesized the small molecule compounds designed by Fujitsu, and confirmed that some of the compounds demonstrated the inhibitory activity desired for drug candidates. Kowa subsequently synthesized multiple small molecule compounds sharing similar chemical structures, and confirmed that a series of the synthesized compounds also showed inhibitory activity. Kowa is currently evaluating the complex structure of these compounds using X-ray crystallography, and plans to optimize the small molecule compounds obtained from this research to reflect the results to the discovery of new drugs. Through this joint research project, RCAST, Fujitsu, and Kowa have succeeded in using IT-based drug discovery to create new small molecule compounds with inhibitory activity against cancer-causing target proteins, and may one day prove effective even against cancers that show resistance to existing drugs.
(1) Inhibitory activity The degree to which a compound binds to a protein thought to cause a specific disease indication and inhibits the function of the protein. Usually expressed in terms of the concentration of the compound.
(2) Drug candidate compound design technology Optimum Packing of Molecular Fragments (OPMF), a software module developed by Fujitsu that designs small molecule compounds that bind to the functional site of proteins that are believed to cause specific disease indications and inhibit the activity of the proteins.
(3) M2BAR A computational method developed by Fujitsu Laboratories for rapidly and accurately predicting the quantitative activity of a compound using multiple binding patterns.
(4) High-precision activity prediction technology Software developed by Fujitsu Laboratories, comprised of MAPLECAFEE, a module that, based on molecular dynamics calculations, predicts the inhibitory activity of drug candidate compounds with a high level of precision that is equivalent to that of biochemical assays, and Force Field Formulator for Organic Molecules (FF-FOM), a module that generates highly detailed parameters for calculating the forces between atoms.
(5) Conformational analysis A method of analyzing the relationship between a compound's conformation (three-dimensional structure) and its potential energy.
About Research Center for Advanced Science and Technology
Research Center for Advanced Science and Technology (RCAST) aims to contribute to the development of science and technology by expeditiously taking on new challenges arising from the advancement of science and coincident changes in society, and by exploring new areas of advanced science and technology for the benefit of humankind and society. Find out more at http://www.rcast.u-tokyo.ac.jp.
Kowa Company, Ltd. is a private multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa has been actively engaging in multidiscipline business including pharmaceuticals, textiles, machinery, and construction material fields. Its pharmaceutical division is focused on research and development for cardiovascular therapeutics, ophthalmology and anti-inflammatory agents. For more information, please see http://www.kowa.co.jp/eng.
About Fujitsu Ltd
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 155,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.5 trillion yen (US$40 billion) for the fiscal year ended March 31, 2017. For more information, please see http://www.fujitsu.com.
* Please see this press release, with images, at:
Research Center for Advanced Science and Technology, The University of Tokyo
Public Relations Ikuko Murayama
E-mail: [email protected]
Public and Investor Relations
Source: Fujitsu Ltd
Sectors: Enterprise IT, BioTech
Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Press Release
More Latest Release >>
NEC Provides Demo System Utilizing MEC to DOCOMO 5G Open Lab Yotsuya
Jul 23, 2018 16:34 JST
Showa Denko Included in Three ESG Indices for Consecutive Years
Jul 23, 2018 16:00 JST
Toyota to Bring Latest Technologies, Toyota Production System to Support Mobility at the Olympic and Paralympic Games Tokyo 2020
Jul 23, 2018 14:03 JST
Fujitsu and NPO SEEDS Asia in AR-Enabled Mobile App Trial to Measure Indian Flood Waters, Visualize Urban Flooding
Jul 23, 2018 12:48 JST
NEC to Revise Operating Segments
Jul 20, 2018 17:31 JST
Rally Finland: Preview Toyota Yaris WRC trio ready for flat-out Finnish push
Jul 20, 2018 17:08 JST
Toyota Motor Corporation Founder Kiichiro Toyoda Inducted into Automotive Hall of Fame
Jul 20, 2018 15:54 JST
Toyota Mobility Foundation Deploys Two- and Four-Wheeler Rental and Ride-Sharing Solutions
Jul 20, 2018 15:11 JST
Fujitsu Joins RE100, a Global Renewable Electricity Initiative
Jul 20, 2018 10:13 JST
Academic, Corporate Collaboration Succeeds at World's Most Efficient Solar Power-Generated Hydrogen Production
Jul 19, 2018 20:07 JST
DOCOMO, Evernote, Marubeni Software & Technology (Thailand) to Offer Evernote Business in Thailand
Jul 19, 2018 16:15 JST
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018
Jul 19, 2018 10:38 JST
Update on Mazda Plant Operations from July 23 Following Record Rains
Jul 18, 2018 18:20 JST
Hitachi Rail Italy Signed a Contract Worth 87 Million Euros for further 12 Leonardo Trains for Milan Metro
Jul 18, 2018 13:51 JST
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ
Jul 18, 2018 12:04 JST
Toyota to Commence Verification Testing with Toyota City for Road Maintenance Inspections Using Vehicle Data Obtained from Connected Cars
Jul 18, 2018 10:42 JST
NEC and dotData Use AI to Accelerate Data Science for the SMBC Group
Jul 17, 2018 11:29 JST
TEPCO Fuel and Power & MHPS Launch Digital Solution Service to Improve Asset Value of Clean Coal Power Plants
Jul 13, 2018 15:51 JST
Toyota Celebrates Teamwork and Inclusivity at the Special Olympics Unified Cup
Jul 13, 2018 09:07 JST
Toyota Mobility Foundation Publishes the "Building Mobility Systems Suitable to Local Communities" Guidebook
Jul 12, 2018 21:29 JST